New Zealand markets closed

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.1700+0.1600 (+5.32%)
As of 02:22PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.0100
Open3.0300
Bid3.1500 x 1200
Ask3.1600 x 800
Day's range2.9200 - 3.1700
52-week range2.9200 - 15.3160
Volume262,372
Avg. volume642,192
Market cap247.37M
Beta (5Y monthly)1.78
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update

    BEDFORD, Mass., May 09, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended March 31, 2022, and provided updates on its ophthalmology pipeline.

  • Business Wire

    Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

    BEDFORD, Mass., May 03, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced two scientific presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting being held May 16-19, 2022 in Washington, D.C. and virtually.

  • Business Wire

    Ocular Therapeutix™ to Report First Quarter 2022 Financial Results

    BEDFORD, Mass., April 26, 2022--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2022 financial results on Monday, May 9, 2022. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30